Skip to main content

Advertisement

SpringerLink
Log in

Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to compare the response to neoadjuvant taxanes and anthracyclines chemotherapy and survival in patients with triple-negative breast cancer (TNBC) and non-TNBC.

Methods

Two hundred and forty-nine patients treated with neoadjuvant chemotherapy were included in this retrospective study. All the patients were classified as TNBC and non-TNBC according to the immunohistochemical results of estrogen receptor (ER), progesterone receptor (PR), and HER2 status. TNBC is defined as the lack of ER, PR, and HER2 expression. The pathological response and long-time survival were compared between TNBC patients and non-TNBC patients.

Results

Among all 249 cases, 54 (21.7%)were TNBC patients, 195 (78.3%) were non-TNBC patients. Compared with non-TNBC patients, the pathological complete response (pCR) rate of patients with TNBC was 25.9%, which was significantly higher than that of patients with non-TNBC (P = 0.019). Patients with TNBC, especially for those with residual disease after chemotherapy, had decreased 5 years’ disease-free survival (DFS) and 5 years’ overall survival (OS) compared with those with non-TNBC (P < 0.05). The 5 years’ DFS and OS of patients who achieve pCR were significantly higher than that of patients with residual disease after chemotherapy (P < 0.05). Patients with TNBC and non-TNBC had similar DFS and OS if pCR achieved.

Conclusion

Patients with TNBC were more sensitive to neoadjuvant docetaxel plus epirubicin chemotherapy. Compared with non-TNBC patients, TNBC patients had increased pCR rate, but were associated with significantly worse survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and Her2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728

    Article  PubMed  Google Scholar 

  • Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903

    Article  PubMed  CAS  Google Scholar 

  • Carey LA, Rugo HS MD, Marcom PK, Marcom PK, Irvin W Jr, Ferraro M, Burrows E, HE X, Perou CM, Winer EP (2008) For the Translational Breast Cancer Research Consortium.TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract 1009). J Clin Oncol 26(15):43

    Google Scholar 

  • Chia K, Tutt A (2007) Triple negative breast cancer: an update. Adv Breast Cancer 4(3):75–80

    Google Scholar 

  • Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rwalinson E, Ping Sun, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434

    Article  PubMed  Google Scholar 

  • Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076–1087

    PubMed  CAS  Google Scholar 

  • Iwase H, Yamamoto Y (2008) Biological characteristics of triple negative breast cancer. Jpn J Breast Cancer 23(2):75–80

    Google Scholar 

  • Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Paul Harkin D (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668

    Article  PubMed  CAS  Google Scholar 

  • Kobayashi S (2008) Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 15:153–158

    Article  PubMed  Google Scholar 

  • Kopetz S, Mita MM, Mok I (2008) First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors (abstract 3577). J Clin Oncol 26(15):172

    Google Scholar 

  • Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Fraser Symmans W, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281

    Article  PubMed  Google Scholar 

  • Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L (2007) Residual ductal carcinoma in situ in patients with Complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin ncol 25:2650–2655

    Article  CAS  Google Scholar 

  • Moynahan ME, Cui TY, Jasin M (2001) Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61:4842–4850

    PubMed  CAS  Google Scholar 

  • Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374

    Article  PubMed  CAS  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  PubMed  CAS  Google Scholar 

  • Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP (2003) BRCA1 functions as a diff erential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221–6228

    PubMed  CAS  Google Scholar 

  • Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32

    Article  PubMed  CAS  Google Scholar 

  • Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

    Article  PubMed  CAS  Google Scholar 

  • Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685

    Article  PubMed  CAS  Google Scholar 

  • Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100:8418–8423

    Google Scholar 

  • Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5:388–393

    Article  PubMed  CAS  Google Scholar 

  • Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM (2009) Clinicopathological features of the triple-negative tumor in Chinese breast cancer patients. Breast Cancer Res Treatment 115:325–333

    Article  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiangxi Road, Guangzhou, 510120, People’s Republic of China

    Jiannan Wu, Shunrong Li, Weijuan Jia & Fengxi Su

Authors
  1. Jiannan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shunrong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weijuan Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fengxi Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fengxi Su.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, J., Li, S., Jia, W. et al. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol 137, 1505–1510 (2011). https://doi.org/10.1007/s00432-011-1029-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-011-1029-6

Keywords

Search

Navigation